Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1Phase 1/2 1

Status

Recruiting 3Active not recruiting 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Tumor-Agnostic 2Breast 2Thoracic 1Sarcoma 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Neoplasms 4Endometrial Neoplasms 4Squamous Cell Carcinoma of Head and Neck 3Head and Neck Neoplasms 3Breast Neoplasms 3Rectal Neoplasms 2Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Pathologic Complete Response 1Ovarian Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Hemangiosarcoma 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Adenocarcinoma, Clear Cell 1

Interventions

pembrolizumab 17Bevacizumab 12Standard of Care 10Cyclophosphamide 9Carboplatin 9Doxorubicin 7Cetuximab 7Nivolumab 6Exercise 6olaparib 5atezolizumab 5Rituximab 5Radiotherapy 5Pemetrexed 5Fluorouracil 5Cisplatin 5durvalumab 4dostarlimab 4abemaciclib 4Temozolomide 4Prednisone 4Paclitaxel 4Leucovorin 4Blood Specimen Collection 4venetoclax 3temsirolimus 3talazoparib 3pertuzumab 3obinutuzumab 3ibrutinib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Neoplasms × dostarlimab × 30 days × Clear all
NCT05277051 2026-05-22

First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors

GlaxoSmithKline

Phase 1 Active not recruiting
152 enrolled
BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Neoplasm Metastasis, Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT06551142 2026-05-22

PanTumor-101

GlaxoSmithKline

Phase 1 Recruiting
845 enrolled
Tumor-Agnostic

Neoplasms

NCT06796907 2026-05-22

BEHOLD-2

GlaxoSmithKline

Phase 1/2 Recruiting
305 enrolled
Tumor-Agnostic

Neoplasms

NCT01042379 2026-05-06

I-SPY

QuantumLeap Healthcare Collaborative

Phase 2 Recruiting
5,000 enrolled
BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡